Patents Assigned to Laboratoire HRA-Pharma
  • Method for on-demand contraception
    Patent number: 10772897
    Abstract: The invention relates to a method for on-demand contraception, which method comprises administering a progestogen agent or progesterone receptor modulator, such as 17a-acetoxy-11b-[4-N, N-dimethylamino-phenyl)-19-norpregna-4, 9-diene-3, 20-dione (ulipristal acetate) in a woman, within 72 hours before an intercourse or within 120 hours after the intercourse.
    Type: Grant
    Filed: December 21, 2018
    Date of Patent: September 15, 2020
    Assignees: Laboratoire HRA-Pharma, The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Andre Ulmann, Erin Gainer, Henri Camille Mathe, Diana Blithe, Lynnette Nieman
  • Method for on-demand contraception
    Patent number: 10159681
    Abstract: The invention relates to a method for on-demand contraception, which method comprises administering a progestogen agent or progesterone receptor modulator, such as 17a-acetoxy-11b-[4-N,N-dimethylamino-phenyl)-19-norpregna-4,9-diene-3,20-dione (ulipristal acetate) in a woman, within 72 hours before an intercourse or within 120 hours after the intercourse.
    Type: Grant
    Filed: February 5, 2016
    Date of Patent: December 25, 2018
    Assignees: Laboratoire HRA-Pharma, The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Andre Ulmann, Erin Gainer, Henri Camille Mathe, Diana Blithe, Lynnette Nieman
  • Method for scheduling ovulation
    Patent number: 9855282
    Abstract: The invention relates to a method for scheduling ovulation in a female subject, which method comprises administering ulipristal acetate (UPA) to the female subject during the follicular phase.
    Type: Grant
    Filed: November 15, 2016
    Date of Patent: January 2, 2018
    Assignee: Laboratoire HRA-Pharma
    Inventors: Delphine Levy, Erin Gainer
  • Ulipristal acetate tablets
    Patent number: 9844510
    Abstract: The invention relates to a pharmaceutical tablet for oral administration comprising ulipristal acetate together with the following excipients: at least one diluent in an amount of 50 to 98.5 wt %, at least one binding agent in an amount of 0 to 10 wt %, at least one disintegrating agent in an amount of 0.5 to 10 wt %, and at least one lubricant in an amount of 0 to 10 wt %.
    Type: Grant
    Filed: June 17, 2016
    Date of Patent: December 19, 2017
    Assignee: Laboratoire HRA-Pharma
    Inventors: Erin Gainer, Helene Guillard, Denis Gicquel, Marianne Henrion, Celine Gnakamene
  • Ulipristal acetate for prevention and treatment of breast tumors
    Patent number: 9814732
    Abstract: The invention relates to the use of ulipristal acetate, or any of its metabolites, in preventing or treating a breast tumor in a patient, preferably a patient that carries a mutation in BRCA1 gene.
    Type: Grant
    Filed: July 29, 2016
    Date of Patent: November 14, 2017
    Assignees: Laboratoire HRA-PHARMA, INSERM (Institut National de la Sante et de la Recherche Medicale)
    Inventors: Michele Resche-Rigon, Delphine Levy, Erin Gainer, Anne Gompel, Patricia Forgez, Laudine Desreumaux-Communal
  • Method for treating uterine fibroids
    Patent number: 9682088
    Abstract: The invention relates to a method for treating uterine fibroids, which method comprises administering to a patient in need thereof, an effective amount of 17?-acetoxy-11?-[4-N,N-dimethylamino-phenyl)-19-norpregna-4,9-diene-3,20-dione (ulipristal) or any metabolite thereof. More particularly, the method is useful for reducing or stopping bleeding in a patient afflicted with uterine fibroids, and/or for reducing the size of uterine fibroids.
    Type: Grant
    Filed: October 1, 2015
    Date of Patent: June 20, 2017
    Assignees: LABORATOIRE HRA-PHARMA, THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES
    Inventors: Lynnette Nieman, Andre Ulmann, Diana Blithe, Erin Gainer
  • Method for on-demand contraception
    Patent number: 9616073
    Abstract: The invention relates to a method for on-demand contraception, which method comprises administering a progestogen agent or progesterone receptor modulator, such as 17a-acetoxy-11b-[4-N,N-dimethylamino-phenyl)-19-norpregna-4,9-diene-3,20-dione (ulipristal acetate) in a woman, within 72 hours before an intercourse or within 120 hours after the intercourse.
    Type: Grant
    Filed: April 13, 2010
    Date of Patent: April 11, 2017
    Assignees: Laboratoire HRA-Pharma, The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Andre Ulmann, Erin Gainer, Henri Camille Mathe, Lynnette Nieman, Diana Blithe
  • Co-micronization product comprising ulipristal acetate
    Patent number: 9610293
    Abstract: The subject of the present invention is a co-micronization product comprising an active ingredient selected from the group consisting of ulipristal acetate, a ulipristal acetate metabolite and mixtures thereof, and a pharmaceutically acceptable solid surfactant. The invention also relates to a pharmaceutical composition comprising said co-micronization product and to the therapeutic uses thereof.
    Type: Grant
    Filed: November 7, 2013
    Date of Patent: April 4, 2017
    Assignee: LABORATOIRE HRA-PHARMA
    Inventors: Florian Battung, Pierre-Yves Juvin, Jérôme Hecq, Aude Colin
  • Method for scheduling ovulation
    Patent number: 9522154
    Abstract: The invention relates to a method for scheduling ovulation in a female subject, which method comprises administering ulipristal acetate (UPA) to the female subject during the follicular phase.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: December 20, 2016
    Assignee: LABORATOIRE HRA-PHARMA
    Inventors: Delphine Levy, Erin Gainer
  • Method for on-demand contraception
    Patent number: 9283233
    Abstract: The invention relates to a method for on-demand contraception, which method comprises administering a progestogen agent or progesterone receptor modulator, such as 17a-acetoxy-11b-(4-N,N-dimethylamino-phenyl)-19-norpregna-4,9-diene-3,20-dione (ulipristal acetate) in a woman, within 72 hours before an intercourse or within 120 hours after the intercourse.
    Type: Grant
    Filed: March 2, 2015
    Date of Patent: March 15, 2016
    Assignees: LABORATOIRE HRA-PHARMA, The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Andre Ulmann, Erin Gainer, Henri Camille Mathe, Diana Blithe, Lynnette Nieman
  • Method for treating uterine fibroids
    Patent number: 9180133
    Abstract: The invention relates to a method for treating uterine fibroids, which method comprises administering to a patient in need thereof, an effective amount of 17?-acetoxy-11?-[4-N,N-dimethylamino-phenyl)-19-norpregna-4,9-diene-3,20-dione (ulipristal) or any metabolite thereof. More particularly, the method is useful for reducing or stopping bleeding in a patient afflicted with uterine fibroids, and/or for reducing the size of uterine fibroids.
    Type: Grant
    Filed: March 7, 2014
    Date of Patent: November 10, 2015
    Assignees: LABORATOIRE HRA-PHARMA, THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
    Inventors: Lynnette Nieman, Andre Ulmann, Diana Blithe, Erin Gainer
  • Method for contraception
    Patent number: 9180131
    Abstract: The invention relates to a method of contraception, which method comprises administering to a woman in need thereof an emergency contraception during one or two days, followed by a prolonged low dosage contraceptive treatment until next menstrual period.
    Type: Grant
    Filed: December 11, 2009
    Date of Patent: November 10, 2015
    Assignee: LABORATOIRE HRA PHARMA
    Inventors: Erin Gainer, André Ulmann, Luc Massart, Héléne Guillard
  • CO-MICRONISATION PRODUCT COMPRISING ULIPRISTAL ACETATE
    Publication number: 20150290218
    Abstract: The subject of the present invention is a co-micronization product comprising an active ingredient selected from the group consisting of ulipristal acetate, a ulipristal acetate metabolite and mixtures thereof, and a pharmaceutically acceptable solid surfactant. The invention also relates to a pharmaceutical composition comprising said co-micronization product and to the therapeutic uses thereof.
    Type: Application
    Filed: November 7, 2013
    Publication date: October 15, 2015
    Applicant: LABORATOIRE HRA-PHARMA
    Inventors: Florian Battung, Pierre-Yves Juvin, Jérôme Hecq, Aude Colin
  • Method for post coital contraception in overweight or obese female subjects using ulipristal acetate
    Patent number: 8962603
    Abstract: The invention provides a method for providing post coital contraception in a female subject, comprising providing the subject with a therapeutically effective amount of ulipristal acetate, wherein the female subject is overweight or obese.
    Type: Grant
    Filed: December 1, 2010
    Date of Patent: February 24, 2015
    Assignee: Laboratoire HRA-Pharma
    Inventors: Delphine Levy, Andre Ulmann, Henri Camille Mathe, Erin Gainer
  • Sustained release compositions containing progesterone receptor modulators
    Patent number: 8865200
    Abstract: Disclosed are sustained release compositions for vaginal or transdermal administration that contain a progesterone receptor modulator such as CDB-2914 (also referred to as VA-2914), and methods of using them for long term contraception or therapeutic purposes. Also disclosed are methods for making the compositions.
    Type: Grant
    Filed: July 8, 2005
    Date of Patent: October 21, 2014
    Assignee: Laboratoire HRA Pharma
    Inventors: Regine Sitruk-Ware, Yun-Yen Tsong
  • METHODS, DOSING REGIMENS AND MEDICATIONS USING ANTI-PROGESTATIONAL AGENTS FOR THE TREATMENT OF DISORDERS
    Publication number: 20140235603
    Abstract: The present invention relates to the treatment of disorders using anti-progestational agents. More specifically, the present invention relates to the treatment of disorders using low doses of anti-progestational agents. Compared to dosages and lengths of treatment taught by the prior art, the described methods, dosing regimens and medications use effective dosages and lengths of treatment that are lower and/or shorter than previously thought possible.
    Type: Application
    Filed: April 24, 2014
    Publication date: August 21, 2014
    Applicant: LABORATOIRE HRA-PHARMA
    Inventor: Richard Hausknecht
  • Ulipristal Acetate Tablets
    Publication number: 20140228335
    Abstract: The invention relates to a pharmaceutical tablet for oral administration comprising ulipristal acetate together with the following excipients: at least one diluent in an amount of 50 to 98.5 wt %, at least one binding agent in an amount of 0 to 10 wt %, at least one disintegrating agent in an amount of 0.5 to 10 wt %, and at least one lubricant in an amount of 0 to 10 wt %.
    Type: Application
    Filed: April 17, 2014
    Publication date: August 14, 2014
    Applicant: Laboratoire HRA PHARMA
    Inventors: Erin Gainer, Helene Guillard, Denis Gicquel, Marianne Henrion, Celine Gnakamene
  • METHOD FOR TREATING UTERINE FIBROIDS
    Publication number: 20140187525
    Abstract: The invention relates to a method for treating uterine fibroids, which method comprises administering to a patient in need thereof, an effective amount of 17?-acetoxy-11?-[4-N,N-dimethylamino-phenyl)-19-norpregna-4,9-diene-3,20-dione (ulipristal) or any metabolite thereof. More particularly, the method is useful for reducing or stopping bleeding in a patient afflicted with uterine fibroids, and/or for reducing the size of uterine fibroids.
    Type: Application
    Filed: March 7, 2014
    Publication date: July 3, 2014
    Applicants: THE USA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES, LABORATOIRE HRA-PHARMA
    Inventors: Lynnette Nieman, Andre Ulmann, Diana Blithe, Erin Gainer
  • Ulipristal acetate tablets
    Patent number: 8735380
    Abstract: The invention relates to a pharmaceutical tablet for oral administration comprising ulipristal acetate together with the following excipients: at least one diluent in an amount of 50 to 98.5 wt %, at least one binding agent in an amount of 0 to 10 wt %, at least one disintegrating agent in an amount of 0.5 to 10 wt %, and at least one lubricant in an amount of 0 to 10 wt %.
    Type: Grant
    Filed: December 8, 2009
    Date of Patent: May 27, 2014
    Assignee: Laboratoire HRA Pharma
    Inventors: Erin Gainer, Helene Guillard, Denis Gicquel, Marianne Henrion, Celine Gnakamene
  • Pharmaceutical tablet
    Patent number: D842453
    Type: Grant
    Filed: September 22, 2017
    Date of Patent: March 5, 2019
    Assignee: Laboratoire HRA-PHARMA
    Inventors: Stéphanie Pradet, Frédérique Welgryn, Suzanne Tran, Christine Seguin